Jinyu Medical Secures Tens of Millions in Pre-A Funding Led by Binghong Capital to Expand Remote Outpatient Services

Recently, VCBeat (WeChat ID:vcbeat) learned that Beijing Jinyu Hospital Management Co., Ltd. (hereinafter referred to as “Jinyu Medical”) has secured tens of millions of yuan inPre-Around of financing, led by Binghong Capital, with follow-on investments from New Momentum Fund and Wu Shichun of Plum Ventures.

According to a previous report by VCBeat (“More Grounded Than Remote Consultations: This Company Will Capture the Next Billion-Dollar Market Through Remote Outpatient Services”), Jinyu Medical primarily focuses on telemedicine’s“Telemedicine Outpatient Services”business. Leveraging this as a breakthrough point, we aim to build an integrated platform offering services such as remote outpatient care, remote emergency care, remote treatment, remote surgery, two-way referral, clinical diagnosis and treatment services, physician education, pharmaceutical distribution, and patient health management.The entire closed-loop ecosystem of telemedicine, artificial intelligence, and big data in healthcare.

Jinyu Medical was founded in September 2017, positioning itself asTightly Integrated Specialty Medical Consortium Service Institutions, after one year of rapid development, has formedA Tripartite Platform Business Model Integrating Technology, Resources, and Services。

Mr. Wang Tiejun, the founder, stated that following this round of financing, Jinyu Medical will implement its “Remote Outpatient Clinic” project in hundreds of hospitals across ten provinces within three major regions nationwide. By leveraging its core telemedicine technologies—such as real-time transmission of dynamic imaging and nationwide triage, queuing, and patient calling systems—the company aims to establish a “clinic-to-clinic” telemedicine platform to serve more medical consortiums and healthcare institutions.

Jinyu Medical’s remote outpatient services currently focus primarily on ophthalmology patients. As of press time, Jinyu Medical has signed contracts with more than 30 Tier II and above hospitals, serving nearly 10,000 primary-care patients.

What lies behind the rapid growth of Jinyu Medical? What do investors see as its core competitive advantages? To find out, VCBeat conducted exclusive interviews with Wang Tiejun, CEO of Jinyu Medical, and the project team at Binghong Capital, to hear their perspectives.

Under the national healthcare reform policy of “initial diagnosis at the primary care level and major diseases treated within the county,” primary hospitals urgently need to enhance their medical capabilities to retain more patients. The emergence of telemedicine is regarded as a new turning point; however, traditional remote consultations have not achieved genuine widespread adoption among patients due to constraints related to timing, workflows, and service models.

Wang Tiejun believes that to truly enable patients to benefit from the development of telemedicine, real-time coordination between upstream and downstream hospitals must be achieved. Jinyu Medical’s telemedicine outpatient model directly integrates into the routine outpatient services of upstream and downstream hospitals, enabling patients at the primary care level toRoutine TelemedicineIn this model, after undergoing initial examinations and the first consultation at a primary care hospital, patients can achieve face-to-face consultations with upstream specialists, accompanied by their physicians, with the assistance of real-time dynamic imaging transmission technology.

Amid the capital winter, the success of this financing round serves as a strong endorsement by the investment community of Jinyu Medical’s strategic positioning and development model. By establishing remote outpatient services to cater to a large volume of outpatients, Jinyu Medical has effectively realized the core objectives of medical consortia: “downward allocation of high-quality resources, initial diagnosis at primary care facilities, and two-way patient referrals.” Building on technical support provided to primary care departments, this model assists grassroots hospitals in developing specialized ophthalmology services, thereby further driving departmental growth. More importantly, under this model, patients have reaped the greatest “health dividends.”

Binghong Capital was established in 2010, with business offices in Beijing, Shanghai, Shenzhen, and Henan Province, covering investment activities across China. The company currently manages over ten funds, with assets under management nearing RMB 5 billion. It has completed more than 70 project investments, and nearly 20 of its portfolio companies have successfully gone public through initial public offerings (IPOs).

Chain-based specialized medical services are a key investment focus for Binghong Capital, which has previously invested in specialized healthcare providers such as Meinian Onehealth and Xichan Plastic Surgery. Its current investment in Jinyu Medical represents part of its strategic layout in the healthcare services sector.

A project lead at Binghong Capital stated that they conducted thorough due diligence on Jinyu, participated in multiple medical consortium meetings, visited hospital administrators and frontline physicians at facilities where Jinyu has established operations, and observed the implementation of remote outpatient services. In their view, there are four key reasons behind Binghong’s investment in Jinyu Medical:

First, remote outpatient services align with national policies and hold promising prospects. Jinyu Medical has seized the opportunity presented by the state’s promotion of medical consortium development, facilitating the practical implementation of such consortia in accordance with the national policy framework for tiered diagnosis and treatment.

Second, it can provide tangible assistance to hospitals and patients across the upstream and downstream care continuum. Remote outpatient services enable primary-care patients to consult with renowned specialists from Beijing’s top-tier (Grade 3A) hospitals without traveling long distances, thereby offering genuine convenience to patients at the grassroots level.

Third, the team boasts extensive experience and a mature business model. Investors believe that Jinyu’s team demonstrates strong execution capabilities, with core members having 10 years of industry experience in telemedicine. Meanwhile, Jinyu’s integrated “three-in-one” business model is mature and competitive.

Fourth, it is highly scalable. The project adopts an asset-light model, enabling large-scale replication and expansion.

Following this round of financing, Binghong Capital will also provide JinYu Medical with support in multiple areas, including strategic planning, business development direction, staffing, business model, and external resources. Most importantly, Binghong Capital is optimistic about JinYu Medical’s future growth and will continue to participate in subsequent investment rounds.